An ethical obligation to ignore the unreliable
- 28 Downloads
Stephen John has recently suggested that the ethics of communication yields important insights as to how values should be incorporated into science. In particular, he examines cases of “wishful speaking” in which a scientific actor (e.g. a tobacco company) endorses unreliable conclusions in order to obtain the consequences of the listener treating the results as credible. He concludes that what is wrong in these cases is that the speaker surreptitiously relies on values not accepted by the hearer, violating what he terms “the value-apt ideal”. I expand on this view by integrating into it Miranda Fricker’s account of testimonial injustice. I find testimonial injustice can arise in a manner unanticipated by Fricker, specifically that a credibility excess given to a speaker typically reduces the ability of others in the epistemic community to transmit knowledge, a phenomenon I term “collateral epistemic injustice”. I argue that this possibility entails that receivers have an ethical obligation to assign credibility judiciously. A further consequence of this view is that the value-apt ideal is insufficient. Because audience members have an obligation to assign credibility judiciously, a speaker cannot merely rely on shared values, they must also be open about the extent to which their conclusions depend on those values. Thus, both wishful speaking and obscuring the value-dependent nature of a conclusion makes one an unreliable source of information. Accordingly, other community members have an ethical obligation to ignore a speaker that frequently engages in either.
KeywordsValues in science Wishful speaking Epistemic injustice Industry-funded science Intransigently biased agents
I would like to thank Steven John, Christopher ChoGlueck, and Kevin Elliott who all responded to questions and corrected (at least some of) the misunderstandings I had of their work. The form and substance of the paper was helped tremendously by insightful feedback from Elizabeth Seger, audiences at “Understanding Epistemic Injustice” conference, The University of Texas (El Paso), The University of Ghent, and two blind reviewers. Finally, I owe my biggest debt of gratitude to Justin Bruner. Not only was he kind enough to supply the graphs and to run the simulations reported in Sect. 3, the core of this paper emerges from our early work on intransigently biased agents. Sections 3–5 were revised and sharpened over multiple drafts and innumerable long conversations with him. Justin spotted numerous gaps in my thinking and though we do not agree on all points contained herein, the paper has been greatly improved by our ongoing disagreement.
- Apfel, R. J., Fisher, S. M., & Fisher, S. (1986). To do no harm: DES and the dilemmas of modern medicine. New Haven: Yale University Press.Google Scholar
- Caplow, T. (1952). Market attitudes: A research report from the medical field. Harvard Business Review,30(6), 105–112.Google Scholar
- CDC. (2012). Center for disease control and prevention. DES Update: Consumers. http://www.cdc.gov/des/consumers/index.html.
- Coady, C. A. (1992). Testimony: A philosophical study. Oxford: Clarendon Press.Google Scholar
- CPC. (1939). Stilbestrol: Preliminary report of the council. Journal of the American Medical Association,113, 2312.Google Scholar
- Craig, E. (1991). Knowledge and the state of nature: An essay in conceptual synthesis. Oxford: Clarendon Press.Google Scholar
- Dutton, D. B. (1992). Worse than the disease: Pitfalls of medical progress. Cambridge: Cambridge University Press.Google Scholar
- Gaffin, Ben, and Associates, American Medical Association, & Pharmaceutical Manufacturers Association. (1958). Attitudes of US physicians toward the American Pharmaceutical Industry. The Author.Google Scholar
- Greenhill, J. (1949). The 1949 yearbook of obstetrics and gynecology. Chicago: Yearbook Publishers.Google Scholar
- Hearings Before Senate Subcommittee on Antitrust and Monopoly. (1961). Washington, DC: US Government Printing.Google Scholar
- Holman, B. (unpublished). Medical knowledge as what doctors know.Google Scholar
- Hume, D (1739/2000). An enquiry concerning human understanding. Oxford: Oxford University Press.Google Scholar
- IARC. International Agency for Research on Cancer. (2012). Diethylstilbestrol. A review of human carcinogens. IARC Monograph Evaluation Carcinogenic Risks for Humans,100, 175–218.Google Scholar
- JAMA (1949). JAMA, 139, 130.Google Scholar
- John, S. (2018b). Science, truth and dictatorship: Wishful thinking or wishful speaking? Studies in History and Philosophy of Science. https://doi.org/10.1016/j.shpsa.2018.12.003.
- John, S. (2018c). Scientific deceit. Synthese. https://doi.org/10.1007/s11229-018-02017-4.
- Kaufman, R. H. (1982). Structural changes of the genital tract associated with in utero exposure to diethylstilbestrol. Obstetrics and Gynecology Annual,11, 187.Google Scholar
- Kaufman, R. H., Adam, E., Hatch, E. E., Noller, K., Herbst, A. L., Palmer, J. R., et al. (2000). Continued follow-up of pregnancy outcomes in diethylstilbestrol-exposed offspring. Obstetrics and Gynecology,96(4), 483–489.Google Scholar
- Langston, N. (2010). Toxic bodies. New Haven: Yale University Press.Google Scholar
- Lasagna, L. (1955). Statistics, sophistication, and sacred cows. Clinical Research Proceedings,3, 185.Google Scholar
- Lexchin, J. (1984). The real pushers: A critical analysis of the Canadian drug industry. Vancouver: New Star Books.Google Scholar
- McGarity, T., & Wagner, W. (2008). Bending science: How special interests corrupt public health research. Cambridge, MA: Harvard University Press.Google Scholar
- Meyers, R. (1983). DES: The bitter pill. New York: Seaview/Putnam.Google Scholar
- Oldani, M. (2002). Tales from the “Script”: An insider/outside view of pharmaceutical sales practice. Kroeber Anthropological Society Papers,92–93, 147–176.Google Scholar
- Podolsky, S. H. (2015). The antibiotic era: Reform, resistance, and the pursuit of a rational therapeutics. Baltimore: JHU Press.Google Scholar
- Reid, D. D. (1955). The use of hormones in the management of pregnancy in diabetics. Lancet,2, 833–836.Google Scholar
- Swyer, G. I. M., & Law, R. G. (1954). An evaluation of the ante-natal use of stilboestrol-preliminary report. Journal of Endocrinology,10, vi–vii.Google Scholar
- Warner, J. H. (2014). The therapeutic perspective: Medical practice, knowledge, and identity in America, 1820–1885. Princeton NJ: Princeton University Press.Google Scholar